trending Market Intelligence /marketintelligence/en/news-insights/trending/YOMoZHw5BvP2hdvAsW16yQ2 content esgSubNav
In This List

Flexion's osteoarthritis drug Zilretta wins US FDA approval

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Flexion's osteoarthritis drug Zilretta wins US FDA approval

The U.S. Food and Drug Administration approved Flexion Therapeutics Inc.'s non-opioid drug Zilretta, an intra-articular injection for osteoarthritis knee pain.

The FDA approval is based upon data from Flexion's pivotal phase 3 clinical trial.

Zilretta's label also includes the results from a trial that examined blood glucose concentrations in patients with type 2 diabetes. The trial found that Zilretta may avoid the spikes in blood sugar associated with the use of corticosteroid treatment in patients with both knee pain and diabetes.

Flexion expects Zilretta will be available in the U.S. by the end of October.